MSP-1014

MSP-1014
Clinical data
Other namesMSP1014; MSP-1014.OX
Routes of
administration		Oral[1][2]
Drug classSerotonin receptor agonist; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen

MSP-1014 is a serotonergic psychedelic which is under development for the treatment of major depressive disorder, other depressive disorders, and anxiety disorders.[3][4][5][1][2]

It is a prodrug of psilocin similarly to psilocybin, and hence acts as a non-selective serotonin receptor agonist, including of the serotonin 5-HT2A receptor.[3][5][2][6]

The drug is under development by Mindset Pharma and Otsuka America Pharmaceutical.[3][4][5] As of January 2024, it is in phase 2 clinical trials for major depressive disorder and is in the preclinical stage of development for anxiety disorders and other depressive disorders.[3][4][5] The chemical structure of MSP-1014 does not yet seem to have been disclosed.[3][4] However, Mindset Pharma patented psilocin derivatives and prodrugs in 2022.[7]

  1. ^ a b Mindset Pharma (14 November 2022). "Mindset Pharma Presents Poster at Neuroscience 2022 Highlighting Preclinical Data on MSP-1014, its Psilocybin-like Lead Drug Candidate". GlobeNewswire News Room (Press release). Retrieved 29 October 2024.
  2. ^ a b c Araujo JA, Higgins GA, de Lannoy IA, Dean I, Atkinson J, Lanthier J, Slassi M. (2022 November 13). 147.05 / JJ5 - The preclinical safety, behavioural and pharmacokinetics properties of MSP-1014, a novel prodrug of psilocin. Neuroscience 2022. https://www.abstractsonline.com/pp8/#!/10619/presentation/70912
  3. ^ a b c d e "MSP 1014". AdisInsight. 9 January 2024. Retrieved 29 October 2024.
  4. ^ a b c d "Delving into the Latest Updates on MSP-1014 with Synapse". Synapse. 26 October 2024. Retrieved 29 October 2024.
  5. ^ a b c d "Mindset Pharma Receives Approval for Phase II Clinical Trial Evaluating MSP-1014 for the Treatment of Major Depressive Disorder". BioSpace. 22 June 2023. Retrieved 29 October 2024. MSP-1014 is a novel and patent-protected prodrug of psilocin, the active metabolite of psilocybin. MSP-1014 is anticipated to exert similar efficacy to psilocybin in improving symptoms of depression. Preclinical studies comparing MSP-1014 to psilocybin suggest that the tolerability of MSP-1014 may be superior to psilocybin.
  6. ^ Dodd S, Norman TR, Eyre HA, Stahl SM, Phillips A, Carvalho AF, et al. (July 2022). "Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy". CNS Spectrums. 28 (4): 416–426. doi:10.1017/S1092852922000888. PMID 35811423.
  7. ^ US 2022/0289774, Slassi A, Araujo J, "Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders", issued 7 March 2023, assigned to Mindset Pharma Inc.